Innoviva, Inc. is a diversified biopharmaceutical company operating through three primary divisions: a core royalties portfolio, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. The royalty division generates revenue from respiratory assets partnered with Glaxo Group Limited (GSK), specifically RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol) and ANORO ELLIPTA (umeclidinium bromide/vilanterol), which are used for the treatment of chronic obstructive pulmonary disease and asthma. The critical care and infectious disease platform, known as Innoviva Specialty Therapeutics (IST), markets five approved products: GIAPREZA (angiotensin II) for septic shock, XACDURO (sulbactam/durlobactam) for hospital-acquired bacterial pneumonia, XERAVA (eravacycline) for complicated intra-abdominal infections, ZEVTERA (ceftobiprole) for staphylococcus aureus bacteremia and other infections, and NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea. The company also holds strategic investments in healthcare companies, including a significant stake in Armata Pharmaceuticals, Inc., which focuses on bacteriophage development. Innoviva serves hospital and clinical markets globally, with products launched in the United States, Europe, and Japan. The company was incorporated in 1996 as Advanced Medicine, Inc., changed its name to Theravance, Inc. in 2002, and rebranded to Innoviva, Inc. in 2016.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage inva.com
Sector Healthcare IR page investor.inva.com
Tags
respiratory royalties, critical care, infectious diseases, antibiotics, septic shock, bacterial pneumonia, gonorrhea, bacteriophages, hospital therapeutics, biopharmaceutical, Innoviva Specialty Therapeutics, IST, RELVAR, BREO ELLIPTA, ANORO ELLIPTA, GIAPREZA, XACDURO, XERAVA, ZEVTERA, NUZOLVENCE, Armata Pharmaceuticals, Basilea Pharmaceutica, Theravance Respiratory Company, Entasis Therapeutics, La Jolla Pharmaceutical Company
Press page —

Metrics

Valuation  
Market cap $ 1.517B
Market cap (USD) $ 1.517B
P/E 9.47
PEG 1.15
P/BV 1.33
P/S 3.46
P/OCF 8.27
P/FCF 7.75
Dividend yield 3.5%
Turnover / mcap —
Returns  
ROE 29.1%
ROI 19.0%
ROIC 9.5%
Profit margin 65.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 8.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 22.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Revenue 411.328M 358.711M 310.463M 331.339M 391.866M 336.794M 261.016M 261.004M 217.217M 133.569M 53.949M 8.433M 4.758M 135.758M 24.512M 24.223M 24.374M 23.096M 22.002M 19.587M 12.054M — —
Net profit 271.165M 23.392M 179.722M 220.262M 368.837M 293.814M 190.993M 406.328M 134.272M 59.536M -18.76M -168.464M -170.701M -18.542M -115.344M -83.862M -85.302M -93.643M -159.997M -166.044M -143.164M -102.654M -70.583M
Free cash flow 195.799M 188.42M 140.653M 201.659M 363.813M 313.1M 257.446M 223.531M 141.749M 60.706M 10.124M -131.412M -132.336M -130.544M -91.966M -76.005M -58.808M -100.942M -114.19M -110.499M -62.088M -49.908M -32.439M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Share price 19.99 17.35 16.04 13.25 17.25 12.39 14.16 17.45 14.19 10.7 10.54 — — — — — — — — — — — —
Price performance 12m 0.15 0.08 0.21 -0.23 0.39 -0.12 -0.19 0.23 0.33 0.02 — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 7.75M — — — — 0.00 96.2M 0.00 192M 0.00
Borrowings, non-current (USD) 708M 574M 383M 377M 386M 395M 444M 446M 256M 258M
Lease liabilities (USD) — — 0.00 — — 106,000 3.69M 2.84M 2.75M 11.3M
Cash and deposits (USD) 118M 73.3M 62.4M 278M 246M 202M 291M 194M 305M 551M
Intangible assets (USD) — — — — — 0.00 253M 230M 208M 182M
Right-of-use assets (USD) — — 0.00 — — 97,000 3.27M 2.54M 2.45M 10.9M
Net debt (borrowings + leases - cash) (USD) 598M 501M 320M 99M 139M 193M 253M 256M 146M -282M
Cash flow detail
Operating cash flow (USD) 61M 142M 224M 257M 313M 364M 202M 141M 189M 197M
Purchases of property, plant and equipment (USD) -278,000 0.00 0.00 -12,000 -13,000 0.00 -67,000 -411,000 -270,000 -1.13M
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -4M 0.00
Change in receivables (cash effect) (USD) 0.00 — — — 0.00 0.00 -3.53M -5.05M -5.94M -14.6M
Change in inventories (cash effect) (USD) 0.00 — — — 0.00 0.00 280,000 -12M -6.81M -12.9M
Change in payables (cash effect) (USD) -690,000 473,000 -590,000 -1,000 56,000 -39,000 92,000 3.78M -4.59M 2.83M
Dividends paid (cash effect) (USD) -960,000 -281,000 -80,000 -11,000 0.00 0.00 — — — —
Share buybacks (cash effect) (USD) -78.1M -97.5M 0.00 0.00 0.00 -394M -8.5M -75.7M -14.8M -4.53M
Interest paid (cash effect) (USD) -48.8M -40.4M -17.9M -11M -9.93M -9.93M -11.7M -11.4M -10.4M -10.4M
Income taxes paid (cash effect) (USD) — — — — 0.00 0.00 -53.9M 0.00 -11.8M -19.1M
Share-based compensation (USD) 8.3M 9.83M 3.23M 2.06M 1.7M 2.02M 7.35M 5.84M 6.37M 9.45M
Operating cash flow before change in receivables (USD) 61M — — — 313M 364M 205M 146M 195M 212M
Free cash flow (OCF - PPE - intangibles) (USD) 60.7M 142M 224M 257M 313M 364M 202M 141M 184M 196M
Income detail
Research and development expense (USD) 1.39M 1.36M 0.00 0.00 1.79M 576,000 41.4M 33.9M 13.7M 30.6M
↳ 5y CAGR -57.8% -59.1% -7.3% -16.2% +98.2% +76.5%
Total comprehensive income (USD) 59.5M 134M 406M 191M 294M 369M 220M 180M 23.4M —
Comprehensive income to owners (USD) 59.5M 134M 395M 157M 224M 266M 214M 180M 23.4M —
Reported Feb 28, 2017 Feb 23, 2018 May 1, 2019 Feb 19, 2020 Feb 28, 2023 Feb 28, 2023 Feb 26, 2025 Feb 26, 2025 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 04, 2026

Download PDF

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth

$58.1 million in quarterly revenue from durable royalty portfolio

Returned capital to shareholders through repurchase of 1.2 million shares in Q3 under $125 million buyback program

BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 4, 2026-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements.

“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales. We are excited about the potential to meaningfully expand the reach of our products and expect operating leverage, supported by sustained fiscal discipline, to strengthen the business’s profitability as revenues grow. Marking another milestone for IST, NUZOLVENCE®, a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea, is now commercially available in the U.S.,” said Pavel Raifeld, Chief Executive Officer of Innoviva.

“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation. To that end, we evaluate new opportunities that can broaden our portfolio and further accelerate growth alongside investments in our high-potential strategic healthcare assets. We also continue to execute on our share repurchase program, reflecting our excitement and conviction in Innoviva’s long-term prospects,” concluded Mr. Raifeld.

Financial Highlights

  • Total revenue: $106.1 million, decreased modestly by 1.6% year over year compared to $107.8 million for the third quarter of 2025, as growth in U.S. net product sales was partially offset with lower royalty revenue and fluctuations in the timing of inventory sales to ex-U.S. partners.

  • **Royalty revenue:**gross royalty revenue from Glaxo Group Limited (“GSK”) remained stable at $58.1 million.

  • Net product sales:$49.4 million, comprising $43.3 million in U.S. net product sales and $6.1 million in ex-U.S. sales. U.S. net product sales increased 45% year-over-year, compared to $29.9 million in the same quarter of 2025. U.S. net product sales primarily consisted of $23.1 million from GIAPREZA®, $16.1 million from XACDURO®, and $3.4 million from XERAVA®.

  • Income from operations: $42.2 million, 21.9% increase compared to $34.6 million for the third quarter of 2025, primarily driven by higher U.S. net product sales, partially offset by increased operating expenses associated with the expansion of commercial activities to support future sales growth.

  • Equity and long-term investments: net unfavorable changes in fair value of equity and long-term investments totaled $139.5 million, primarily attributable to a decline in the stock price of Armata Pharmaceuticals at quarter-end.As of September 30, 2026**,**Innoviva’s strategic healthcare investments were valued at $535.5 million, consisting of $323.7 million invested in Armata Pharmaceuticals, $179.9 million in other strategic equity and convertible debt investments, and $31.9 million in investments held by ISP Fund.

  • Net income: net loss of $73.9 million, or $1.03 basic loss per share, driven primarily by a decrease in fair value of equity and long-term investments.

  • **Cash and cash equivalents:**totaled $581.4 million. Royalty and net product sales receivables totaled $102.1 million as of September 30, 2026.

Business Highlights

  • Innoviva Specialty Therapeutics (IST)

  • Updated 2026 guidance from the Infectious Diseases Society of America (IDSA) further strengthens the clinical positioning of XACDURO® (sulbactam/durlobactam for injection), reaffirming its use with imipenem or meropenem as the preferred treatment for invasive carbapenem-resistant Acinetobacter baumannii (CRAB) infections. By recommending high-dose ampicillin-sulbactam combination regimens only as temporary bridging therapy when XACDURO® is not immediately available, the updated guidance underscores the importance of timely hospital access and supports XACDURO®’s opportunity for broader adoption and continued commercial growth.

  • The 2026 Antimicrobial Resistance Threats Report from the Centers for Disease Control and Prevention identifies four pathogens in its highest threat category, requiring “urgent and aggressive action.” IST markets therapies targeting two of these pathogens — XACDURO® for carbapenem-resistant Acinetobacter and NUZOLVENCE® for drug-resistant Neisseria gonorrhoeae — reinforcing its leadership in addressing critical gaps in the treatment of drug-resistant infections.

  • NUZOLVENCE® (zoliflodacin) is now commercially available in the U.S., expanding IST’s commercial portfolio. Initial commercial efforts are focused on establishing market access, distribution and dispensing infrastructure to help eligible patients receive treatment when prescribed and support adoption over time.

  • IST presented data at IDWeek 2026, the annual meeting of IDSA, the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS) for ZEVTERA® and NUZOLVENCE®, highlighting evidence generation across antimicrobial-resistant and difficult-to-treat infections.

  • XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) were nominated as finalists for the 2026 Prix Galien USA Award in the “Best Pharmaceutical Product” category, marking the third consecutive year an IST product has been recognized by the renowned Galien Foundation.

  • Capital Allocation

  • During the third quarter of 2026, Innoviva repurchased 1,226,948 shares for $26.3 million under its $125 million share repurchase program. Since inception, and through the end of the third quarter, the Company has repurchased 3,829,116 shares for $82.7 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook.

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA®(ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

Forward-looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

| INNOVIVA, INC. |

| Condensed Consolidated Statements of Income |

| (in thousands, except per share data) |

| (Unaudited) |

| | | | | | | | | |

| | | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| Revenue: | | | | | | | | |

| Royalty revenue, net (1) | | $ | 54,657 | | | $ | 59,896 | | | $ | 166,158 | | | $ | 181,583 | |

| Net product sales | | | 49,444 | | | | 47,294 | | | | 142,586 | | | | 113,066 | |

| License and other revenue | | | 2,019 | | | | 610 | | | | 14,961 | | | | 2,066 | |

| Total revenue | | | 106,120 | | | | 107,800 | | | | 323,705 | | | | 296,715 | |

| Cost of products sold (inclusive of amortization of inventory fair value adjustments) | | | 15,038 | | | | 25,643 | | | | 52,994 | | | | 45,075 | |

| Amortization of acquired intangible assets | | | 6,700 | | | | 6,618 | | | | 19,880 | | | | 19,640 | |

| Gross profit | | | 84,382 | | | | 75,539 | | | | 250,831 | | | | 232,000 | |

| Operating expenses: | | | | | | | | |

| Selling, general and administrative | | | 37,015 | | | | 27,291 | | | | 104,024 | | | | 81,194 | |

| Research and development | | | 5,214 | | | | 13,670 | | | | 15,645 | | | | 26,049 | |

| Total operating expenses | | | 42,229 | | | | 40,961 | | | | 119,669 | | | | 107,243 | |

| Income from operations | | | 42,153 | | | | 34,578 | | | | 131,162 | | | | 124,757 | |

| Changes in fair values of equity method investments, net | | | (97,585 | ) | | | 30,751 | | | | (71,769 | ) | | | 30,284 | |

| Changes in fair values of equity and long-term investments, net | | | (41,904 | ) | | | 31,510 | | | | (37,482 | ) | | | (22,509 | ) |

| Interest and dividend income | | | 5,316 | | | | 5,472 | | | | 23,902 | | | | 14,935 | |

| Interest expense | | | (5,472 | ) | | | (4,015 | ) | | | (16,381 | ) | | | (13,389 | ) |

| Other expense, net | | | (118 | ) | | | (479 | ) | | | (499 | ) | | | (2,252 | ) |

| Income (loss) before income taxes | | | (97,610 | ) | | | 97,817 | | | | 28,933 | | | | 131,826 | |

| Income tax benefit (expense) | | | 23,722 | | | | (7,909 | ) | | | 354 | | | | (24,814 | ) |

| Net income (loss) | | $ | (73,888 | ) | | $ | 89,908 | | | $ | 29,287 | | | $ | 107,012 | |

| | | | | | | | | |

| Net income (loss) per share: | | | | | | | | |

| Basic | | $ | (1.03 | ) | | $ | 1.30 | | | $ | 0.40 | | | $ | 1.65 | |

| Diluted | | $ | (1.03 | ) | | $ | 1.08 | | | $ | 0.40 | | | $ | 1.35 | |

| | | | | | | | | |

| Shares used to compute net income (loss) per share: | | | | | | | | |

| Basic | | | 72,068 | | | | 69,058 | | | | 73,209 | | | | 64,901 | |

| Diluted | | | 72,068 | | | | 84,964 | | | | 73,969 | | | | 84,576 | |

| (1) Total net revenue is comprised of the following (in thousands): |

| | | | | | | | | |

| | | Three Months Ended | | Nine Months Ended |

| | September 30, | | September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| | | (unaudited) | | (unaudited) |

| Royalties | | $ | 58,113 | | | $ | 63,352 | | | $ | 176,526 | | | $ | 191,951 | |

| Amortization of capitalized fees | | | (3,456 | ) | | | (3,456 | ) | | | (10,368 | ) | | | (10,368 | ) |

| Royalty revenue, net | | $ | 54,657 | | | $ | 59,896 | | | $ | 166,158 | | | $ | 181,583 | |

| | | | | | | | | | | | | | | | | |

| INNOVIVA, INC. |

| Condensed Consolidated Balance Sheets |

| (in thousands) |

| (unaudited) |

| | | | | |

| | | September 30, | | December 31, |

| | | 2026 | | 2025 |

| Assets | | | | |

| Cash and cash equivalents | | $ | 581,394 | | | $ | 550,941 | |

| Royalty and product sale receivables | | | 102,130 | | | | 93,317 | |

| Inventory | | | 42,838 | | | | 39,172 | |

| Prepaid expense and other current assets | | | 37,225 | | | | 28,358 | |

| Current portion of ISP Fund investments | | | 8,667 | | | | 15,727 | |

| Property and equipment, net | | | 2,038 | | | | 1,555 | |

| Equity method and equity and long-term investments | | | 526,791 | | | | 598,223 | |

| Capitalized fees | | | 45,770 | | | | 56,138 | |

| Right-of-use assets | | | 10,100 | | | | 10,929 | |

| Goodwill | | | 17,905 | | | | 17,905 | |

| Intangible assets | | | 162,276 | | | | 182,156 | |

| Other assets | | | 792 | | | | 40,744 | |

| Total assets | | $ | 1,537,926 | | | $ | 1,635,165 | |

| | | | | |

| | | | | |

| Liabilities and stockholders’ equity | | | | |

| Other current liabilities | | $ | 44,795 | | | $ | 43,808 | |

| Accrued interest payable | | | 231 | | | | 1,618 | |

| Deferred revenue | | | 5,004 | | | | 4,270 | |

| Convertible senior notes, due 2028, net | | | 258,822 | | | | 257,731 | |

| Deferred tax liabilities, net | | | 6,914 | | | | 31,793 | |

| Income tax payable, long term | | | 19,406 | | | | 57,013 | |

| Other long term liabilities | | | 65,236 | | | | 66,091 | |

| Stockholders’ equity | | | 1,137,518 | | | | 1,172,841 | |

| Total liabilities and stockholders’ equity | | $ | 1,537,926 | | | $ | 1,635,165 | |

| | | | | |

| INNOVIVA, INC. |

| Cash Flows Summary |

| (in thousands) |

| (unaudited) |

| | | |

| | | Nine Months Ended September 30, |

| | | 2026 | | 2025 |

| Net cash provided by operating activities | | $ | 128,952 | | | $ | 142,417 | |

| Net cash provided by (used in) investing activities | | | (23,685 | ) | | | 16,860 | |

| Net cash provided by (used in) financing activities | | | (74,814 | ) | | | 12,272 | |

| Net change | | $ | 30,453 | | | $ | 171,549 | |

| Cash and cash equivalents at beginning of period | | | 550,941 | | | | 304,964 | |

| Cash and cash equivalents at end of period | | $ | 581,394 | | | $ | 476,513 | |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104246173/en/

Media Amanda Brown Galgay Vice President, Communications [email protected]

Investors Irwin Tendler Head of Investor Relations Executive Director, Corporate Development [email protected]

Source: Innoviva, Inc.

Innoviva NASDAQ: INVA

$19.10 -0.14 (-0.73%)

Nov 6, 2026 4:00 PM EST

Minimum 15 minutes delayed. Source: LSEG

Sign up to receive important email alerts & updates from Innoviva.

Sign up now

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Back

Vendor Search

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Reject All Allow All

Oct 19, 2026

Download PDF

Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 19, 2026-- Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Convention Center in Washington, D.C.

The presentations cover two FDA-approved antibiotics marketed by Innoviva Specialty Therapeutics, ceftobiprole (ZEVTERA®) and zoliflodacin (NUZOLVENCE®), and represent the company’s ongoing commitment to clinically meaningful data generation following regulatory approval.

“Antimicrobial resistance remains one of the most urgent global health challenges, requiring continued innovation and rigorous evidence generation. The data we are presenting at IDWeek demonstrate the breadth of our work across infectious diseases, from evaluating ceftobiprole against contemporary clinical isolates and advancing its use in pediatric patients to sharing new insights from our zoliflodacin clinical program,” said David Altarac, M.D., Chief Medical Officer at Innoviva Specialty Therapeutics. “Together, these findings reflect our commitment to advancing meaningful treatment options for clinicians and patients facing serious infectious diseases.”

Poster Presentations

Title: In Vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary U.S. Clinical Isolates Collected in 2025 Following FDA Approval Date: Thursday, October 22, 2026 Time: 12:15 PM – 1:30 PM ET Location: Poster Hall B–C

Title: Pediatric Ceftobiprole Dose Selection — Model-Based Approach for Staphylococcus aureus Bacteremia Including Right-Sided Infective Endocarditis Date: Thursday, October 22, 2026 Time: 12:15 PM – 1:30 PM ET Location: Poster Hall B–C

Title: Ceftobiprole for Pediatric ABSSSI — Informing Ceftobiprole Use in Pediatric Acute Bacterial Skin and Skin Structure Infections Through Adult and Pediatric Data Date: Saturday, October 24, 2026 Time: 12:15 PM – 1:30 PM ET Location: Poster Hall B–C

Oral Presentation

Title: Zoliflodacin Maintains High Rates of Microbiologic Eradication of Urogenital Neisseria gonorrhoeae in Patients Co-infected with Chlamydia trachomatis Date: Saturday, October 24, 2026 **Time:**2:15 PM – 2:30 PM ET Location: Room 206

For additional information or to speak with a Medical Affairs or Commercial team representative, please stop by IDWeek booth #515 or visit www.innovivaspecialtytherapeutics.com and follow us on LinkedIn.

About ZEVTERA® (ceftobiprole medocaril sodium for injection)

Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced-generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria. Outside the U.S., the brand is currently approved and marketed in several European countries and beyond as ZEVTERA® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Basilea has entered into license and distribution agreements covering more than 80 countries.

INDICATIONS & USAGE

Indications

ZEVTERA® (ceftobiprole medocaril sodium for injection), for intravenous use, is indicated for the treatment of:

  • Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.

  • Adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, and Klebsiella pneumoniae.

  • Adult and pediatric patients (3 months to less than 18 years) with community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible isolates), Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Escherichia coli, and Klebsiella pneumoniae.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

ZEVTERA is contraindicated in patients with a known history of severe hypersensitivity to ZEVTERA, or to other members of the cephalosporin class.

Warnings and Precautions

  • Increased mortality with unapproved use in ventilator-associated bacterial pneumonia (VABP) Patients: The safety and effectiveness of ZEVTERA for the treatment of VABP has not been established and the use of ZEVTERA for VABP is not approved.

  • Serious hypersensitivity reactions, including anaphylaxis, were observed in ZEVTERA-treated patients in clinical trials. Serious and occasionally fatal hypersensitivity reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with ZEVTERA is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or other beta-lactam antibacterial drugs should be made. Maintain clinical supervision if this product is to be given to a penicillin- or other beta-lactam-allergic patient, because cross sensitivity among beta-lactam antibacterial agents has been established. Discontinue ZEVTERA if a hypersensitivity reaction occurs, and institute appropriate treatment.

  • Seizures and other adverse central nervous system (CNS) reactions have been reported during treatment with ZEVTERA and other cephalosporins. If CNS adverse reactions, including seizures, occur, evaluate patients to determine whether ZEVTERA should be discontinued.

  • Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZEVTERA, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with ZEVTERA should be assessed.

Adverse Reactions

  • SAB (adult patients): The most common adverse reactions occurring in ≥ 2% of adult patients were anemia, nausea, hypokalemia, vomiting, hepatic enzyme and bilirubin increased, diarrhea, blood creatinine increased, hypertension, leukopenia, pyrexia, abdominal pain, fungal infection, headache, and dyspnea.

  • ABSSSI (adult patients): The most common adverse reactions occurring in ≥ 2% of adult patients were nausea, diarrhea, headache, injection site reaction, hepatic enzyme increase, rash, vomiting, and dysgeusia.

  • CABP (adult and pediatric patients 3 months to less than 18 years of age):

  • Adult Patients: The most common adverse reactions occurring in ≥ 2% of adult patients were nausea, hepatic enzyme increased, vomiting, diarrhea, headache, rash, insomnia, abdominal pain, phlebitis, hypertension, and dizziness.

  • Pediatric Patients: The most common adverse reactions occurring in ≥ 2% of pediatric patients were vomiting, headache, hepatic enzyme increased, diarrhea, infusion site reaction, phlebitis, and pyrexia.

About NUZOLVENCE® (zoliflodacin) for oral suspension

NUZOLVENCE is a first-in-class, single-dose, oral antibiotic FDA-approved for the treatment of uncomplicated urogenital gonorrhea, including strains resistant to current first-line therapies. NUZOLVENCE is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg. The NUZOLVENCE mechanism of action is distinct from that of currently approved antibiotics and has demonstrated activity against drug-resistant Neisseria gonorrhoeae.

Important Safety Information (ISI)

Indication and Usage

Indication

NUZOLVENCE® is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg.

Usage to Reduce Development of Drug-Resistant Bacteria: To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Contraindications

Known history of hypersensitivity to NUZOLVENCE.

Concomitant use with moderate or strong CYP3A4 inducers because this is predicted to result in decreased plasma concentrations of zoliflodacin and may reduce the NUZOLVENCE efficacy.

Warnings and Precautions

  • Embryo-Fetal Toxicity: Potential Risk for Pregnant Females

  • Based on data from animal studies, NUZOLVENCE may cause fetal harm when administered to a pregnant female at clinically relevant doses. Avoid use during pregnancy. Advise pregnant females about the potential risk to the fetus with maternal exposure to NUZOLVENCE. Obtain a pregnancy test prior to initiation in persons of reproductive potential.

  • Embryo-Fetal Toxicity: Potential Risk Related to Males with Female Partners of Reproductive Potential:

  • Based on data from an animal toxicity study, the risk of early pregnancy loss may be increased in female partners of males treated with NUZOLVENCE. Advise males with female partners of reproductive potential to use effective contraception for at least 3 months after NUZOLVENCE administration.

  • Testicular Toxicity and Risks to Male Fertility:

  • Based on findings from animal studies, NUZOLVENCE may cause testicular toxicity and impair male fertility. An assessment of spermatogenesis has not been conducted in humans. Advise males that NUZOLVENCE may cause testicular toxicity and impair male fertility.

  • Hypersensitivity Reactions:

  • Hypersensitivity reactions, including rash and pruritus, have been reported in patients receiving NUZOLVENCE. Before therapy with NUZOLVENCE is instituted, carefully inquire about previous hypersensitivity reactions to NUZOLVENCE. If an allergic reaction to NUZOLVENCE occurs, discontinue NUZOLVENCE and institute appropriate supportive measures.

  • Clostridioides difficile Infection (CDI):

  • CDI has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

  • Development of Drug-Resistant Bacteria:

  • Prescribing NUZOLVENCE in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥2%) are headache, dizziness, nausea, and diarrhea. Laboratory abnormalities (neutropenia, leukopenia) were also observed.

Drug Interactions

Concomitant use with moderate or strong CYP3A4 inducers is contraindicated.

Use in Specific Populations

  • Pregnancy: Based on findings from animal studies, NUZOLVENCE may cause fetal malformations or increased embryo-fetal loss when administered to a pregnant female. A postmarketing descriptive pregnancy safety study is available for NUZOLVENCE. If exposure occurs during pregnancy, pregnant females or their healthcare providers should report the pregnancy to Entasis Therapeutics at 1-800-651-3861.

  • Lactation: There are no data on the presence of zoliflodacin in either human or animal milk, effects on the breastfed infant, or effects on milk production. If NUZOLVENCE is present in breast milk, intestinal flora alteration in the breastfed infant could occur.

  • Females and Males of Reproductive Potential: Based on animal studies, NUZOLVENCE may cause fetal malformations when administered to a pregnant female at clinically relevant doses. Additionally, based on data from an animal study, the risk of early pregnancy loss may be increased in partners of males treated with NUZOLVENCE.

  • Pregnancy Testing: Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with NUZOLVENCE.

  • Contraception: Advise males with female partners of reproductive potential to use effective contraception for at least 3 months after their single-dose treatment of NUZOLVENCE.

  • Infertility: Based on data from repeat-dose animal toxicity and fertility studies, NUZOLVENCE may cause testicular toxicity and impair male fertility.

  • Pediatric Use: The safety and effectiveness of NUZOLVENCE in pediatric patients younger than 12 years of age or weighing less than 35 kg have not been established.

  • Geriatric Use: Clinical studies of NUZOLVENCE did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients.

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:

| Innoviva Specialty Therapeutics™ 1-800-651-3861 [email protected] | | U.S. Food and Drug Administration 1-800-FDA-1088 www.fda.gov/medwatch |

About Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliates, include GIAPREZA® (angiotensin II), XERAVA® (eravacycline), XACDURO® (sulbactam for injection; durlobactam for injection), and NUZOLVENCE® (zoliflodacin). Innoviva Specialty Therapeutics also markets ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva Specialty Therapeutics, please visit www.innovivaspecialtytherapeutics.com.

Forward-Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261019935081/en/

Media Amanda Galgay Vice President, Communications [email protected]

Investors Irwin Tendler Head of Investor Relations Executive Director, Corporate Development [email protected]

Source: Innoviva Specialty Therapeutics

Innoviva NASDAQ: INVA

$21.16 +0.04 (+0.19%)

Oct 29, 2026 11:08 AM EDT

Minimum 15 minutes delayed. Source: LSEG

Sign up to receive important email alerts & updates from Innoviva.

Sign up now

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Back

Vendor Search

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Reject All Allow All

Sep 02, 2026

Download PDF

BURLINGAME, Calif.--(BUSINESS WIRE)--Sep. 2, 2026-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

Citi's 2026 Biopharma Back to School ConferenceFormat: 1x1 meetings Date: Wednesday, September 9, 2026

Cantor Global Healthcare ConferenceFormat: Fireside chat Date: Thursday, September 10, 2026 Time: 8:00 a.m. Eastern Time

H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Presentation Date: Monday, September 14, 2026 Time: 12:00 p.m. Eastern Time

Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: 1x1 meetings Date: Tuesday, September 15, 2026

A live webcast of the presentations can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. An archived replay of the webcasts will be available following each presentation date.

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260902630238/en/

Investors and media contact Irwin Tendler Head of Investor Relations Executive Director, Corporate Development [email protected]

Source: Innoviva, Inc.

Innoviva NASDAQ: INVA

$21.16 +0.04 (+0.19%)

Oct 29, 2026 11:08 AM EDT

Minimum 15 minutes delayed. Source: LSEG

Sign up to receive important email alerts & updates from Innoviva.

Sign up now

Privacy Preference Center

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Back

Vendor Search

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Reject All Allow All

Prompts

Innoviva, Inc. (ticker INVA), listed in United States.

Company History

Date Change Detail
Jan 8, 2016 Renamed THERAVANCE INC → INNOVIVA, INC.

ETFs Holding Innoviva, Inc.

ETF Weight in ETF Shares Market value As of
SIXS 2.05% 156,615 $ 2.971M Nov 12, 2026
HSMV 0.99% 2,965 $ 54.823K Nov 16, 2026
ECML 0.96% 63,176 $ 1.16M Nov 18, 2026
DSMC 0.56% 31,615 $ 717.977K Jun 30, 2026
SQLV 0.47% 5,885 $ 133.648K Jun 30, 2026
JPSV 0.41% 6,295 $ 115.199K Nov 17, 2026
AFSM 0.40% 31,565 $ 583.637K Nov 16, 2026
VFMV 0.39% 84,775 $ 1.761M Aug 31, 2026
SIXL 0.36% 40,053 $ 759.805K Nov 12, 2026
BSVO 0.28% 373,691 $ 6.84M Nov 18, 2026
RUSC 0.21% 7,443 $ 169.031K Jun 30, 2026
SEIS 0.16% 41,976 $ 953.275K Jun 30, 2026
DFSV 0.10% 1,434,945 $ 27.221M Nov 12, 2026
AVSC 0.08% 141,742 $ 2.621M Nov 16, 2026
RESM 0.08% 125 $ 2,838.75 Jun 30, 2026
PSC 0.07% 76,749 $ 1.743M Jun 30, 2026
DFAT 0.06% 1,058,288 $ 20.076M Nov 12, 2026
VFVA 0.05% 21,696 $ 450.626K Aug 31, 2026
DFAS 0.03% 549,616 $ 10.426M Nov 12, 2026
AVUV 0.02% 372,350 $ 6.885M Nov 16, 2026
SFGV 0.02% 11,321 $ 210K Nov 18, 2026
DXUV 0.02% 63,187 $ 1.199M Nov 12, 2026
FESM 0.02% 41,440 $ 941.102K Jun 30, 2026
MSSM 0.01% 4,436 $ 92.136K Aug 31, 2026
EBI 0.01% 3,883 $ 80.65K Aug 31, 2026
AVUS 0.01% 45,167 $ 835.138K Nov 16, 2026
DFAC 0.01% 331,560 $ 6.29M Nov 12, 2026
DFUV 0.01% 53,396 $ 1.013M Nov 12, 2026
DCOR 0.00% 116,555 $ 2.211M Nov 12, 2026
DFAU 0.00% 20,704 $ 392.755K Nov 12, 2026
DFUS 0.00% 25,044 $ 475.085K Nov 12, 2026